Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users
- PMID: 22658145
- DOI: 10.1016/j.jacl.2012.03.003
Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users
Abstract
Background: Statins substantially reduce the risk of cardiovascular disease and are generally well-tolerated. Despite this, many patients discontinue therapy. A better understanding of the characteristics of current and former statin users may be helpful for formulating strategies to improve long-term adherence.
Objective: The Understanding Statin Use in America and Gaps in Education (USAGE) survey assessed the attitudes, beliefs, practices, and behavior of current and former statin users.
Methods: Individuals 18 years or older who reported a history of high cholesterol and current or former statin use were identified within a registered consumer panel cohort in the United States and invited to participate in an Internet survey.
Results: Of the 10,138 respondents, 8918 (88%) were current statin users and 1220 (12%) were former users. Participants (mean age 61 years) were predominantly white (92%), female (61%), of middle income (median $44,504/yr), and had health insurance (93%). Among current users, 95% took a statin alone, and 70% had not missed a dose in the past month. Although ∼70% reported that their physicians had explained the importance of cholesterol levels for their heart health former users were less satisfied with the discussions (65% vs. 83%, P < .05). Muscle-related side effects were reported by 60% and 25% of former and current users, respectively (P < .05). Nearly half of all respondents switched statins at least once. The primary reason for switching by current users was cost (32%) and the primary reason for discontinuation was side effects (62%).
Conclusions: This survey provides important insights into behavior and attitudes among current and former statin users and the results suggest that more effective dialogue between healthcare providers and patients may increase persistence of statin use, particularly when the patient has concerns about side effects and drug costs.
Copyright © 2012 National Lipid Association. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education.J Clin Lipidol. 2013 Sep-Oct;7(5):472-83. doi: 10.1016/j.jacl.2013.03.001. Epub 2013 Mar 13. J Clin Lipidol. 2013. PMID: 24079289
-
Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.Am J Geriatr Pharmacother. 2005 Dec;3(4):218-28. Am J Geriatr Pharmacother. 2005. PMID: 16503317 Clinical Trial.
-
Prospective analysis of LDL-C goal achievement and self-reported medication adherence among statin users in primary care.Clin Ther. 2011 Sep;33(9):1180-9. doi: 10.1016/j.clinthera.2011.07.007. Epub 2011 Aug 12. Clin Ther. 2011. PMID: 21840055 Clinical Trial.
-
Management of statin-intolerant patient.Panminerva Med. 2012 Jun;54(2):105-18. Panminerva Med. 2012. PMID: 22525565 Review.
-
How do we improve patient compliance and adherence to long-term statin therapy?Curr Atheroscler Rep. 2013 Jan;15(1):291. doi: 10.1007/s11883-012-0291-7. Curr Atheroscler Rep. 2013. PMID: 23225173 Free PMC article. Review.
Cited by
-
Statin-Associated Muscle Symptoms: Identification and Recommendations for Management.Curr Atheroscler Rep. 2024 Nov 18;27(1):5. doi: 10.1007/s11883-024-01246-y. Curr Atheroscler Rep. 2024. PMID: 39556289 Review.
-
Review of Evolocumab for the Reduction of LDL Cholesterol and Secondary Prevention of Atherosclerotic Cardiovascular Disease.Rev Cardiovasc Med. 2024 May 23;25(5):190. doi: 10.31083/j.rcm2505190. eCollection 2024 May. Rev Cardiovasc Med. 2024. PMID: 39076473 Free PMC article. Review.
-
PCSK9 Inhibitor: Safe Alternative to Fill the Treatment Gap in Statin-Limited Conditions?Rev Cardiovasc Med. 2022 Nov 9;23(11):380. doi: 10.31083/j.rcm2311380. eCollection 2022 Nov. Rev Cardiovasc Med. 2022. PMID: 39076187 Free PMC article. Review.
-
The Dynamics of Cardiovascular Risk-An Analysis of the Prospective Urban Rural Epidemiology (PURE) Poland Cohort Study.J Clin Med. 2024 Jun 26;13(13):3728. doi: 10.3390/jcm13133728. J Clin Med. 2024. PMID: 38999293 Free PMC article.
-
Overlapping Pattern of the Four Individual Components of Dyslipidemia in Adults: Analysis of Nationally Representative Data.J Clin Med. 2024 Jun 20;13(12):3624. doi: 10.3390/jcm13123624. J Clin Med. 2024. PMID: 38930152 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous

